Drug intelligence / Profile preview

MBTC-CR-EXO

Development stage: Unknown
Lead developer: Stemmedicare
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Ophthalmic, Intravitreal

Overview

MBTC-CR-EXO is an exosome-based therapeutic candidate developed by Stemmedicare for the treatment of ophthalmic disorders. It consists of extracellular vesicles (EVs) designed to promote tissue repair and regeneration. The program is currently in clinical development for indications including corneal disease, corneal regeneration, and age-related macular degeneration (AMD). By leveraging the regenerative properties of stem cell-derived exosomes, MBTC-CR-EXO aims to provide a cell-free alternative to traditional stem cell therapies, potentially offering improved safety and stability profiles for ocular applications.

Beyond the preview

Go deeper on MBTC-CR-EXO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MBTC-CR-EXO.

Explore the full profile